{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:45:54Z","timestamp":1785444354931,"version":"3.56.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijantimicag.2023.106940","type":"journal-article","created":{"date-parts":[[2023,7,29]],"date-time":"2023-07-29T11:20:46Z","timestamp":1690629646000},"page":"106940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety of high loading doses of teicoplanin: POSY-TEICO, a prospective, multicentre, observational study"],"prefix":"10.1016","volume":"62","author":[{"given":"R\u00e9my","family":"Gauzit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marmar","family":"Kabir-Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6966-7167","authenticated-orcid":false,"given":"Federico","family":"Pea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3617-5411","authenticated-orcid":false,"given":"Pierre","family":"Tattevin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106940_bib0001","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3947\/ic.2014.46.1.35","article-title":"Therapeutic drug concentrations of teicoplanin in clinical settings","volume":"46","author":"Nah","year":"2014","journal-title":"Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0002","article-title":"Committee for Medicinal Products for Human Use (CHMP). Targocid Art 30\u2014CHMP Opinion, Summary of Product Characteristics, Labelling and Package Leaflet","year":"2021","journal-title":"Last updated in"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0003","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007022.pub2","article-title":"Teicoplanin versus vancomycin for proven or suspected infection","author":"Cavalcanti","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0004","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1128\/AAC.34.11.2114","article-title":"Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses","volume":"34","author":"Outman","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0005","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2165\/00003088-199018030-00002","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"18","author":"Rowland","year":"1990","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0006","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0007","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijantimicag.2008.05.012","article-title":"Gauteng Understanding Teicoplanin Serum Levels Study Group. Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis","volume":"32","author":"Brink","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0008","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00003088-200443060-00004","article-title":"Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages","volume":"43","author":"Pea","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0009","first-page":"15","article-title":"Pharmacokinetic\/pharmacodynamic analysis of teicoplanin in patients with MRSA infections","volume":"8","author":"Matsumoto","year":"2016","journal-title":"Clin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0010","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/jac\/dkq266","article-title":"Analyses of teicoplanin concentrations from 1994 to 2006 from a UK assay service","volume":"65","author":"Tobin","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0011","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ijantimicag.2012.05.025","article-title":"Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation","volume":"40","author":"Yamada","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0012","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1128\/AAC.00168-11","article-title":"Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial","volume":"55","author":"Bosso","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0013","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clinthera.2011.12.013","article-title":"Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database","volume":"34","author":"Cano","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0014","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4212\/cjhp.v67i2.1340","article-title":"Identification of risk factors for nephrotoxicity in patients receiving extended-duration, high-trough vancomycin therapy","volume":"67","author":"Contreiras","year":"2014","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1517\/14740330903413514","article-title":"Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections","volume":"9","author":"Hermsen","year":"2010","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0016","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0017","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0018","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1592\/phco.31.5.441","article-title":"Validation of the effectiveness of a vancomycin nomogram in achieving target trough concentrations of 15\u201320 mg\/L suggested by the vancomycin consensus guidelines","volume":"31","author":"Kullar","year":"2011","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0019","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/phar.1423","article-title":"Vancomycin-associated nephrotoxicity in adult medicine patients: incidence, outcomes, and risk factors","volume":"34","author":"Meaney","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0021","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jhm.946","article-title":"Elevated vancomycin trough is not associated with nephrotoxicity among inpatient veterans","volume":"7","author":"Prabaker","year":"2012","journal-title":"J Hosp Med"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0022","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0023","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000077807","article-title":"Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to Gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation","volume":"50","author":"D'Antonio","year":"2004","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0024","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1128\/AAC.35.11.2246","article-title":"Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity","volume":"35","author":"Kureishi","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0025","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jac\/dkg147","article-title":"Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose","volume":"51","author":"Pea","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0026","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jiac.2013.08.006","article-title":"High-dose regimen to achieve novel target trough concentration in teicoplanin","volume":"20","author":"Ueda","year":"2014","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106940_bib0027","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1128\/AAC.35.3.451","article-title":"Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts","volume":"35","author":"Van der Auwera","year":"1991","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002194?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002194?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:47:48Z","timestamp":1760377668000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923002194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0924857923002194"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106940","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of high loading doses of teicoplanin: POSY-TEICO, a prospective, multicentre, observational study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106940"}}